Clinical Trials
6 trialsNCT05889390 2026-05-15
NeoHTerMa
Semmelweis University
Phase 2/3 Active not recruiting
NCT06926868 2026-04-30
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT03150576 2022-11-14
PARTNER
Cambridge University Hospitals NHS Foundation Trust
Phase 2/3 Recruiting
NCT01057069 2022-10-12
neo-TN
The Netherlands Cancer Institute
Phase 2/3 Active not recruiting
NCT00448266 2021-01-22
Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT01881230 2019-02-21
tnAcity
Celgene
Phase 2/3 Completed